GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hologic Inc (NAS:HOLX) » Definitions » Net Cash per Share

Hologic (Hologic) Net Cash per Share : $-8.03 (As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Hologic Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Hologic's Net Cash per Share for the quarter that ended in Dec. 2023 was $-8.03.

The historical rank and industry rank for Hologic's Net Cash per Share or its related term are showing as below:

HOLX's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 6.93
* Ranked among companies with meaningful Price-to-Net-Cash only.

Hologic Net Cash per Share Historical Data

The historical data trend for Hologic's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hologic Net Cash per Share Chart

Hologic Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.91 -14.72 -13.92 -7.51 -5.79

Hologic Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.12 -6.36 -5.68 -5.79 -8.03

Competitive Comparison of Hologic's Net Cash per Share

For the Medical Instruments & Supplies subindustry, Hologic's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hologic's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Hologic's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Hologic's Price-to-Net-Cash falls into.



Hologic Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Hologic's Net Cash per Share for the fiscal year that ended in Sep. 2023 is calculated as

Net Cash per Share (A: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(2722.5-4122.4-0)/241.709
=-5.79

Hologic's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1932.1-3815.7-0)/234.544
=-8.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hologic  (NAS:HOLX) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Hologic Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Hologic's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Hologic (Hologic) Business Description

Traded in Other Exchanges
Address
250 Campus Drive, Marlborough, MA, USA, 01752
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Executives
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Scott T Garrett director 35 CROSBY DRIVE, BEDFORD MA 01730
Stephen P Macmillan director, officer: President and CEO 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Essex D Mitchell officer: Div. President, GYN Surgical 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Nanaz Mohtashami director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jennifer M Schneiders officer: President, Diag. Solutions 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Benjamin Jordan Cohn officer: Principal Accounting Officer 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Stacey D. Stewart director 5920 WALHONDING ROAD, BETHESDA MD 20816
Elisabeth A Hellmann officer: SVP, Human Resources 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kevin R Thornal officer: Div. President, Diagnostics 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
John M. Griffin officer: General Counsel 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Karleen Marie Oberton officer: Corp. VP, Finance & Acconting 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Erik S Anderson officer: Div. Pres., Breast & Skeletal 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jan Verstreken officer: Group President, International 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Allison P Bebo officer: SVP, Human Resources 250 CAMPUS DRIVE, MARLBOROUGH MA 01752